Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 As a Marker of Early Tumor Relapse in Breast Cancer Patients

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2007 Sep 6

PMID 17785550

Citations 64

Authors

Mark A Watson

Lourdes R Ylagan

Kathryn M Trinkaus

William E Gillanders

Michael J Naughton

Katherine N Weilbaecher

Timothy P Fleming

Rebecca L Aft

Affiliations

Soon will be listed here.

Abstract

Purpose: Micrometastatic cells detected in the bone marrow have prognostic significance in breast cancer. These cells are heterogeneous and likely do not exhibit uniform biological behavior. To understand the molecular diversity of disseminated cancer cells that reside in bone marrow, we enriched this cell population and did global gene expression profiling in the context of a prospective clinical trial involving women with clinical stage II/III breast cancer undergoing neoadjuvant chemotherapy.

Experimental Design: Enrichment of TACSTD1 (EpCAM)-expressing cells from bone marrow of breast cancer patients was achieved using immunomagnetic beads. Gene expression profiles were compared between enriched cell populations and whole bone marrow from 5 normal volunteers and 23 breast cancer patients after neoadjuvant chemotherapy treatment. Enriched cells from bone marrow samples of breast cancer patients before treatment or at 1 year follow-up were also analyzed (total of 87 data sets). The expression of transcripts specifically detected in enriched cell populations from breast cancer patients was correlated with 1-year clinical outcome using quantitative reverse transcription-PCR in an independent cohort of bone marrow samples.

Results: Analysis of EpCAM-enriched bone marrow cells revealed specific expression of a subgroup of transcripts, including the metastasis regulator, TWIST1. Most transcripts identified, including TWIST1, were not expressed in enriched populations of bone marrow from normal volunteers, suggesting that this expression profile reflects a signature of breast cancer bone marrow micrometastases that persist after chemotherapy. In an independent set of bone marrow samples obtained before any treatment, TWIST1 expression correlated with early disease relapse.

Conclusions: Disseminated breast cancer cells present in bone marrow after chemotherapy possess unique transcriptional signatures. Genes whose expression is overrepresented in these cell populations, such as TWIST1, may prove to be excellent markers of early distant relapse in breast cancer patients.

Citing Articles

Anti-migration and anti-invasion effects of LY-290181 on breast cancer cell lines through the inhibition of Twist1.

Park J, Lee S, Yoon H, Kang E, Cho S BMB Rep. 2023; 56(7):410-415.

PMID: 37357535 PMC: 10390291.

NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer.

Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S Oncol Rev. 2022; 16:10568.

PMID: 36531159 PMC: 9756851. DOI: 10.3389/or.2022.10568.

Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study.

Nordgard O, Lapin M, Tjensvoll K, Oltedal S, Edland K, Neverdahl N BMC Cancer. 2022; 22(1):609.

PMID: 35659265 PMC: 9166481. DOI: 10.1186/s12885-022-09714-x.

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow.

Volmer L, Koch A, Matovina S, Dannehl D, Weiss M, Welker G Cancers (Basel). 2022; 14(3).

PMID: 35158902 PMC: 8833450. DOI: 10.3390/cancers14030635.

Chemoresistance is mediated by ovarian cancer leader cells in vitro.

Karimnia N, Wilson A, Green E, Matthews A, Jobling T, Plebanski M J Exp Clin Cancer Res. 2021; 40(1):276.

PMID: 34470672 PMC: 8408956. DOI: 10.1186/s13046-021-02086-3.

References

Klein C, Seidl S, Petat-Dutter K, Offner S, Geigl J, Schmidt-Kittler O . Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol. 2002; 20(4):387-92. DOI: 10.1038/nbt0402-387. View

Nygaard V, Hovig E . Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling. Nucleic Acids Res. 2006; 34(3):996-1014. PMC: 1363777. DOI: 10.1093/nar/gkj499. View

Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H . High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004; 86(3):207-13. DOI: 10.1023/B:BREA.0000036787.59816.01. View

Braun S, Hepp F, Sommer H, Pantel K . Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer. 1999; 84(1):1-5. DOI: 10.1002/(sici)1097-0215(19990219)84:1<1::aid-ijc1>3.0.co;2-a. View

Phadke P, Mercer R, Harms J, Jia Y, Frost A, Jewell J . Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res. 2006; 12(5):1431-40. PMC: 1523260. DOI: 10.1158/1078-0432.CCR-05-1806. View

Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C . The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer. 2001; 92(1):46-53. DOI: 10.1002/1097-0142(20010701)92:1<46::aid-cncr1290>3.0.co;2-6. View

Elias M, Tozer K, Silber J, Mikheeva S, Deng M, Morrison R . TWIST is expressed in human gliomas and promotes invasion. Neoplasia. 2005; 7(9):824-37. PMC: 1501937. DOI: 10.1593/neo.04352. View

Hajra K, Fearon E . The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002; 62(6):1613-8. View

Welm B, Tepera S, Venezia T, Graubert T, Rosen J, Goodell M . Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol. 2002; 245(1):42-56. DOI: 10.1006/dbio.2002.0625. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F . Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 2000; 18(1):80-6. DOI: 10.1200/JCO.2000.18.1.80. View

12.

Barrallo-Gimeno A, Nieto M . The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005; 132(14):3151-61. DOI: 10.1242/dev.01907. View

13.

Woelfle U, Breit E, Pantel K . Influence of immunomagnetic enrichment on gene expression of tumor cells. J Transl Med. 2005; 3(1):12. PMC: 555956. DOI: 10.1186/1479-5876-3-12. View

14.

Roodman G . Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-64. DOI: 10.1056/NEJMra030831. View

15.

Yang J, Mani S, Liu Donaher J, Ramaswamy S, Itzykson R, Come C . Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-39. DOI: 10.1016/j.cell.2004.06.006. View

16.

Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C . Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res. 2003; 9(7):2598-604. View

17.

Pantel K, Otte M . Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Semin Cancer Biol. 2001; 11(5):327-37. DOI: 10.1006/scbi.2001.0388. View

18.

Wang X, Ling M, Guan X, Tsao S, Cheung H, Lee D . Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene. 2004; 23(2):474-82. DOI: 10.1038/sj.onc.1207128. View

19.

Kang Y, Siegel P, Shu W, Drobnjak M, Kakonen S, Cordon-Cardo C . A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3(6):537-49. DOI: 10.1016/s1535-6108(03)00132-6. View

20.

Gebauer G, Fehm T, Merkle E, Beck E, Lang N, Jager W . Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol. 2001; 19(16):3669-74. DOI: 10.1200/JCO.2001.19.16.3669. View